山外山8月22日报收16.27元，较前一交易日下跌1.63%。当日成交量为105590手，成交金额达1.71亿 元。 风险提示：股市有风险，投资需谨慎。 来源:金融界 资金流向方面，山外山当日主力资金净流出1038.47万元，近五日累计净流出4867.53万元。 该公司属于医疗器械行业，专注于血液净化设备及耗材的研发生产。公开资料显示，二季度末基本养老 保险基金一六零二二组合新进成为山外山第十大流通股东，持有200.45万股，占流通股比例0.85%。 ...

Group 1 - The stock price of Sino Medical as of August 22, 2025, is 32.70 yuan, down by 1.52 yuan, representing a decline of 4.44% from the previous trading day [1] - The opening price for the day was 33.50 yuan, with a highest price of 34.56 yuan and a lowest price of 32.41 yuan, resulting in a trading volume of 605,087 lots and a total transaction amount of 2.01 billion yuan [1] - Sino Medical operates in the medical device industry, focusing on the research, production, and sales of interventional medical devices, with products covering cardiovascular and cerebrovascular fields [1] Group 2 - On August 22, 2025, the net outflow of main funds from Sino Medical was 208.97 million yuan, accounting for 1.54% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow of main funds reached 1.31 billion yuan, representing 9.64% of the circulating market value [1]

证券代码：600055 证券简称：万东医疗 公告编号：2025-038 北京万东医疗科技股份有限公司 关于以集中竞价交易方式回购股份方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 回购股份金额：人民币 3,000 万元（含）-6,000 万元（含）。 ? 回购股份资金来源：公司自有资金。 ? 回购股份价格：不超过25元/股，该价格不高于董事会通过回购股 份决议日前30个交易日公司股票交易均价的150%。 ? 回购股份方式：集中竞价交易方式。 ? 回购股份期限：自董事会审议通过本次回购方案之日起 12 个月内。 ? 相关股东是否存在减持计划：经公司问询，公司董事、高级管理人 员、控股股东、实际控制人在未来3个月、未来6个月不存在减持计划。若 上述主体后续拟实施股份减持计划的，相关方及公司将严格按照相关规定 及时履行信息披露义务。 ? 相关风险提示： 导致本次回购方案无法顺利实施的风险； 及时到位，导致回购方案无法按计划实施的风险； 能存在回购方案无法顺利实施或者根据规则变更或终止本次回购方案的 ...

Group 1 - The stock price of Shuoshi Biological as of August 22, 2025, closed at 63.56 yuan, down 1.00% from the previous trading day [1] - The company opened at 64.42 yuan, reached a high of 64.72 yuan, and a low of 63.52 yuan, with a trading volume of 1.11 billion yuan and a turnover rate of 2.07% [1] - Shuoshi Biological specializes in the research, production, and sales of in vitro diagnostic reagents, covering areas such as infectious diseases and tumor markers [1] Group 2 - The company has recently sparked market discussions due to its dividend plan, proposing a cash dividend of 34 yuan for every 10 shares, totaling 285 million yuan, with a dividend payout ratio of 7142.28% [1] - Notably, the company's net profit for the first half of the year was only 3.99 million yuan, indicating that the dividend amount significantly exceeds its current profit level [1] - On August 22, the net outflow of main funds for Shuoshi Biological was 13.31 million yuan, with a cumulative net outflow of 48.88 million yuan over the past five days [1]

在全球化战略的驱动下，鱼跃医疗持续加大对海外市场的资源配置，面向全球招募专业人才，组建本地 化团队促进文化协同。数据显示，公司上半年实现海外营收6.07亿元，同比增长26.63%，并取得国际注 册认证85项，为新品的全球推广提供支撑。下半年公司还将继续加大海外团队建设力度和属地化销售网 络布局，推动海外业务的扎根与发展。 上半年，鱼跃医疗在AI医疗方面的布局取得阶段性突破。依托在医疗器械领域二十余年的专业技术和 临床数据积累，公司将人工智能、大数据、物联网等前沿技术融入运营管理与产品开发全流程，提升产 品的智能化水平。同时，公司高度重视具备连续性监测功能的产品研发，正积极开展涉及血糖、血压、 血氧等指标的AI智能穿戴医疗设备研发工作。 鱼跃医疗还表示，在生态构建层面，公司正逐步打造"硬件+软件+数据"的一体化健康管理生态体系， 推出鱼跃AI Agent健康管家应用，通过整合旗下多品类医疗设备的数据接口，实现健康数据的采集与管 理、分析与解读，使得用户黏性与使用频次稳步提升，并成为连接公司产品与用户需求的重要纽带。 8月22日晚间，鱼跃医疗（002223）发布2025年半年度报告，上半年，公司实现营业收入46. ...

Group 1 - The latest stock price of Wandong Medical is 18.05 yuan, up 0.84% from the previous trading day, with an opening price of 17.89 yuan, a high of 18.14 yuan, and a low of 17.86 yuan, with a trading volume of 98,145 hands and a transaction amount of 177 million yuan [1] - Wandong Medical focuses on the research, production, and sales of medical imaging equipment, including CT, MRI, and DR devices, and has made significant technological advancements, including the clinical validation of the world's first helium-free superconducting MRI and the application of multiple AI technologies [1] - The latest semi-annual report for 2025 shows that the company achieved an operating income of 843 million yuan in the first half of the year, a year-on-year increase of 20.46%, but the net profit attributable to shareholders decreased by 39.46% to 51.3 million yuan [1] - In the second quarter, the operating income was 470 million yuan, a year-on-year increase of 20.0%, while the net profit attributable to shareholders dropped by 68.4% to 16.25 million yuan [1] - The company's R&D investment increased by 59.16% year-on-year, with an R&D intensity of 15% [1] Group 2 - The net inflow of main funds for Wandong Medical today was 11.07 million yuan, with a cumulative net inflow of 8.30 million yuan over the past five days [2]

| 股票简称：万东医疗 | | 证券代码：600055 | | --- | --- | --- | | 华泰联合证券有限责任公司 | | | | 关于 | | | | 北京万东医疗科技股份有限公司 | | | | 向2025年股票期权激励计划 | | | | 激励对象授予预留股票期权 | | | | 之 | | | | 独立财务顾问报告 | | | | 二零二五年八月 | | | | （二）关于本次授予事项与股东大会审议通过的激励计划是否存在差异的说明 | | ... 8 | | 一、释义 | | | | 本报告中，除非文义载明，下列简称具有如下含义： | | | | 万东医疗、公司 | | 指 北京万东医疗科技股份有限公司 | | 北京万东医疗科技股份有限公司 | | 2025 年股票期权激励计划（草 | | 本激励计划、本计划 | | 指 | | 案） | | | | | | 公司授予激励对象在未来一定期限内以预先确定的价格和条件购 | | 股票期权、期权 | | 指 | | 买公司一定数量股票的权利 | | | | | | 按照本激励计划规定，获得股票期权的公司（含子公司）董事、 | | 激励对象 | ...

北京万东医疗科技股份有限公司 激励对象名单（预留授予日） 一、激励对象名单及分配情况 占本激励计划拟 占本激励计划 获授的股票期权 二、核心骨干人员、董事会认为需要激励的其他人员名单（以下排名不分先后） 序号 姓名 激励对象类别 北京万东医疗科技股份有限公司 董事会 数量（万份） 量的比例 本总额的比例 核心骨干人员（14 人） 120 11.11% 0.17% 注：上表中部分合计数与各明细数相加之和在尾数上如有差异，系百分比结果四舍五入所致。 职 务 授出全部权益数 预留授予时股 ...

证券代码：600055 证券简称：万东医疗 编号：临2025-037 北京万东医疗科技股份有限公司 关于向 2025 年股票期权激励计划 激励对象授予预留股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责 任。 重要内容提示： ? 预留授予日：2025年8月22日 ? 授予数量： 120万份 ? 行权价格：15.05元/份 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、 《北京万东医疗科技股份有限公司2025年股票期权激励计划（草案）》（ 以下简称"本次激励计划"或"激励计划（草案）"）等的相关规定，北 京万东医疗科技股份有限公司（以下简称"公司"）董事会认为本次激励 计划预留授予条件已经成就。根据公司2024年年度股东大会的授权，公司 于2025年8月22日召开第十届董事会第十次会议，审议通过了《关于向2025 年股票期权激励计划激励对象授予预留股票期权的议案》，确定以2025年 万份，行权价格为15.05元/份。现将有关情况公告如下： 一、本次激励计划已履行的审批程序和信息披露情况 《关于公司﹤20 ...

Core Viewpoint - The company is committed to enhancing quality and efficiency while returning value to investors, aligning with national policies and market demands to drive high-quality development and protect investor rights [1]. Group 1: Strategic Focus and Business Development - The company focuses on the development of medical endoscopes and optical products, emphasizing innovation in optical technology and digital imaging [1]. - In 2024, the company expanded its endoscope product line, obtaining registration certificates for various endoscopes, including thoracic and abdominal endoscopes, hysteroscopes, and bladder endoscopes [1]. - The company has established a remote interactive platform for surgical diagnosis and treatment, integrating automatic microscopic scanning and endoscopic systems [2]. Group 2: Innovation and R&D - The company applied for 42 new patents and received 32 new authorized patents, including 12 invention patents, which account for 37.50% of the newly authorized patents [3]. - The company collaborates with external institutions for innovation, establishing a clinical anatomy training center with a medical college to enhance clinical, research, and educational activities [3]. Group 3: Investor Protection Measures - The company has implemented a stable dividend policy, distributing cash dividends to shareholders for five consecutive years, with a proposed cash dividend of 0.60 yuan per share for 2024 [4][5]. - The company has initiated a share repurchase plan, with a total of 1,387,000 shares repurchased, representing 0.6110% of the total share capital [5][6]. - The company emphasizes high-quality information disclosure and investor communication, ensuring transparency and responsiveness to investor inquiries [6][7]. Group 4: Corporate Governance - The company has established a governance structure that includes a shareholders' meeting, board of directors, supervisory board, and independent directors, ensuring clear responsibilities and coordination [8]. - The company plans to optimize its governance structure in 2025, including revising its articles of association and adjusting internal supervisory mechanisms [8].